



- (51) **International Patent Classification:**
C12N 15/86 (2006.01) C12N 15/90 (2006.01)
- (21) **International Application Number:**
PCT/US2023/065689
- (22) **International Filing Date:**
12 April 2023 (12.04.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/330,245 12 April 2022 (12.04.2022) US
- (71) **Applicant: GENZYME CORPORATION** [US/US]; 450 Water Street, Cambridge, MA 02141 (US).
- (72) **Inventors: CHOUDHURY, Sourav, Roy;** c/o Sanofi, Patent Department, 450 Water Street, Cambridge, MA 02141 (US). **MOTWANI, Mona;** c/o Sanofi, Patent Department, 450 Water Street, Cambridge, MA 02141 (US). **MUELLER, Christian;** c/o Sanofi, Patent Department, 450 Water Street, Cambridge, MA 02141 (US). **REED, John;** c/o Sanofi, Patent Department, 450 Water Street, Cambridge, MA 02141 (US).
- (74) **Agent: SNYDER, Seth et al.;** Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

- (54) **Title:** USE OF AN IRAK4 MODULATOR FOR GENE THERAPY

**FIG. 6A**

(57) **Abstract:** Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK degrader with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK degrader in combination with a gene therapy agent.

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))